Drug Type Bispecific antibody |
Synonyms TATX-23 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Preclinical | US | 30 Jan 2022 | |
Inflammation | Preclinical | US | 30 Jan 2022 | |
Infectious Diseases | Discovery | CA | - |